L-Arginine alpha-ketoglutarate (2:1), commonly designated AAKG 2:1, is a crystalline salt comprising 2 mol L-arginine per 1 mol alpha-ketoglutaric acid. The substance is supplied under CAS 16856-18-1 and is represented by the nominal empirical formula C₁₇H₃₄N₈O₉, with a formula weight of 494.5 g·mol⁻¹. Commercial food-grade material is a white to off-white crystalline powder with a typical anhydrous assay of 98.0%–102.0% by HPLC and a pH of 6.5–7.5 in 10% aqueous solution. Model designations such as AAKG-2:1-FG or L-arginine alpha-ketoglutarate powder refer to the same 2:1 molar salt when the certificate of analysis documents the alpha-ketoglutarate content by organic acid HPLC or titration.

The product is intended for oral dietary supplement manufacturing, principally dry-blended pre-workout powders, amino acid premixes, and compressed tablets. Formulations frequently include 1.5–3.0 g of AAKG 2:1 per serving, although the actual dose is determined by the desired L-arginine mass, the pH profile of the finished drink or tablet, and the presence of other basic amino acids. The material is not specified as a sterile injectable component and should not be used outside a demonstrated food-grade quality system.

The 2:1 stoichiometry gives a theoretical L-arginine mass fraction of approximately 70.4 g per 100 g of compound, with the remaining mass composed primarily of the alpha-ketoglutarate fraction and associated water. This distinguishes AAKG 2:1 from L-arginine hydrochloride, which provides approximately 82.7 g L-arginine per 100 g, and from L-arginine free base, which provides 100 g L-arginine per 100 g. The lower arginine mass fraction is offset by a reduced chloride load and a less acidic solution profile; however, published clinical data for this specific 2:1 salt is limited.

What Specifications Are Typically Applied to Food-Grade 2:1 AAKG?

Certificates of analysis for food-grade AAKG 2:1 normally list identity, assay, loss on drying, residue on ignition, elemental impurities, particle-size distribution, and microbial limits. Identity is confirmed by mid-infrared spectrophotometry against a qualified reference substance, with the principal N-H and carboxylate stretching bands compared using attenuated total reflectance. Assay is performed by high-performance liquid chromatography, commonly with a reversed-phase C18 column and UV detection at 205 nm or charged aerosol detection. The result is calculated on the anhydrous basis. Loss on drying is determined according to USP 731, and residue on ignition according to USP 281. Elemental impurities are controlled under USP 232/233 or ICH Q3D, with limits indexed to the maximum daily intake of the finished formulation. Microbial enumeration is performed according to USP 2021 and USP 2022.

A typical HPLC method for assay uses a phosphate or ion-pair mobile phase and a sample concentration near 0.5 mg/mL. The L-arginine peak area is quantified against a certified reference standard. Because alpha-ketoglutarate has weak UV absorption, its content is verified by stoichiometric calculation or a separate organic acid method, and the certificate of analysis should state which approach is used. The powder specification below represents common food-grade control ranges; supplier-specific limits may differ.

The analytical profile is intended for dry dietary supplement manufacturing. Material received in multi-wall kraft bags with polyethylene liners should be sampled according to ANSI/ASQ Z1.4 General Inspection Level I, and the loss-on-drying value should be rechecked after any bag is open for more than 8 h at ambient relative humidity above 60%. If the product exceeds the specified loss-on-drying limit, pre-drying in a vacuum dryer at 40–50 °C for 2–4 h is typical. The drying temperature should not exceed 60 °C, because discoloration and arginine degradation may occur.

Packaging is typically food-grade multi-wall paper sacks with low-density polyethylene liners, net weights of 25 kg or 50 lb. The product should be stored in a dry, cool warehouse with temperature below 25 °C and relative humidity below 50%. Pallet loads should be kept away from direct sunlight and from temperature cycling, which can cause condensation inside the liner. Under these conditions, a retest interval of 12–24 months is common; after the first retest, the product may be extended according to the supplier stability program. Published long-term stability data for this exact salt in finished dietary supplement matrices is limited.

When 2:1 AAKG Replaces Arginine HCl in Aqueous and Dry-Mix Systems

Replacement calculations should start with the theoretical arginine mass fraction: 70.4 g arginine per 100 g AAKG 2:1 versus 82.7 g arginine per 100 g L-arginine hydrochloride. A formulation containing 3.0 g of L-arginine hydrochloride supplies approximately 2.48 g of L-arginine; an equivalent arginine dose requires approximately 3.52 g of AAKG 2:1. This adjustment changes scoop weight, powder volume, and the resulting pH of the finished drink mix. In 10% aqueous solution, AAKG 2:1 typically falls in the range 6.5–7.5, while L-arginine hydrochloride is commonly reported in the 5.5–7.0 range. The higher pH reduces the buffering requirement in some fruit-flavored systems but does not eliminate the use of citric acid or malic acid as flavor acids.

The alpha-ketoglutarate fraction is a dicarboxylic acid salt and may interact with hard-water cations in reconstituted drinks. A slight haze can form in high-calcium water; published data for this specific product in beverage matrices is limited. Formulators should run clarity tests at the intended use concentration in water of 150–300 mg/L hardness and after hot/cold cycling if the product is packaged as a ready-to-drink beverage intermediate.

In effervescent systems, AAKG 2:1 does not generate carbon dioxide when mixed with citric acid alone; the reaction requires sodium bicarbonate or another carbonate source. The salt form changes the final beverage pH and sodium load. AAKG 2:1 does not contribute chloride, whereas L-arginine hydrochloride contributes approximately 17.3 g chloride per 100 g of salt. However, L-arginine itself has a bitter, slightly soapy taste, and the alpha-ketoglutarate fraction can add a faint savory note. Flavor masking with acidulants, citrus flavors, or taste-modulating agents is generally required. Organoleptic performance should be evaluated after storage at 30 °C and 65% RH for 3–6 months, because Maillard-type reactions with reducing sugars can shift color and flavor over time.

When comparing certificates of analysis, the specification for the 2:1 salt should include molar ratio verification. If only total L-arginine content is measured, a material that is a 1:1 alpha-ketoglutarate salt or a blend of L-arginine and alpha-ketoglutaric acid could pass the same arginine assay. Suppliers should state the alpha-ketoglutarate content by titration or organic acid HPLC. AAKG 1:1 has a lower arginine mass fraction and a different solution pH; it is not interchangeable with AAKG 2:1 in formulations where stoichiometry affects pH and label claims.

In dry powder systems, AAKG 2:1 is added after flow aids and before hydrophobic lubricants. If the process area cannot be kept below 50% RH, closed vacuum-transfer systems are preferred to open auger feed. Segregation can occur when the particle-size difference between AAKG 2:1 and coarse carriers exceeds 150 µm; pre-sieving through 40 mesh and post-blend assay of 10 sampling points are therefore used. These process limits are derived from blending practice rather than a single standardized test.

Direct Compression Failure Modes at Elevated Relative Humidity

Direct compression of AAKG 2:1 is technically feasible but sensitive to tooling temperature, lubrication, and ambient moisture. When relative humidity exceeds 55%, surface moisture can promote sticking to punch faces and die walls. On rotary tablet presses with turret speed above 30 RPM, the dwell time is short but frictional heat may raise the powder bed temperature by 2–5 °C. This is sufficient to increase sticking when the loss-on-drying value is above 0.3%. Tablet presses with 10 mm or larger flat-faced convex punches are more likely to show sticking than smaller deep-concave punches because the ejection force is higher. In one industrial run, sticking was eliminated by reducing press speed to 20 RPM, adding 0.5% magnesium stearate, and installing dehumidified air knives at the feed frame. Published data for this specific configuration is limited; the required lubrication level should be confirmed by compression trials.

Granulation can reduce segregation and improve flow, but wet granulation with AAKG 2:1 requires close control of water quantity because the alpha-ketoglutarate salt is partially soluble. High-shear mixers, twin-screw granulators, and fluid-bed dryers are used in amino acid tablet production; the granulation endpoint should be controlled by impeller torque or power consumption rather than fixed time. Published data for this specific product in continuous twin-screw granulation is limited, so scale-up trials should be run with the exact formulation and target moisture specification.

For tablets containing AAKG 2:1, testing should include tablet hardness, friability according to USP 1216, disintegration according to USP 701, and dissolution where a finished product specification exists. Typical acceptance targets are hardness of 60–90 N, friability below 0.8%, and disintegration within 30 min in water at 37 °C. These values are not unique to AAKG 2:1; they are general tablet quality targets that must be revalidated for each formulation. The product may contain residual alpha-ketoglutarate, which can affect the pH of disintegration media and should be recorded in the batch record.

Finished dietary supplement products containing AAKG 2:1 are subject to current good manufacturing practice under 21 CFR Part 111. Material suppliers should provide a food-grade certificate of analysis, a statement of allergen cross-contact, and a heavy-metals declaration consistent with USP 232 or ICH Q3D. The substance is not covered by a pharmacopoeial monograph in the United States Pharmacopeia, so harmonization between supplier and finished-product specifications is necessary before release. Batch-to-batch variance in bulk density, particle-size distribution, and pH should be monitored by incoming-material control charts; a deviation of more than 10% from the qualified value for bulk density is considered significant for dry-blend segregation control.